SNAP-8 · Acetyl Octapeptide-3 · Argireline Variant
Snap-8 (Acetyl Octapeptide-3) is a cosmetic peptide developed by Lipotec (now Lubrizol) as a topical anti-wrinkle ingredient. The 8-amino-acid sequence (Ac-Glu-Glu-Met-Gln-Arg-Arg-Lys-Trp) is engineered to inhibit SNARE complex formation in facial muscle cells - mimicking the mechanism by which botulinum toxin (Botox) blocks acetylcholine release at neuromuscular junctions, but at much lower potency and via direct SNARE inhibition rather than enzymatic cleavage.
Starting dose. 5-10% topical formulation
Apply to expression-line areas (forehead, around eyes, glabella) AM and PM. Combine with moisturizer and SPF. Continuous application required - effects fade upon discontinuation.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Snap-8 inhibits SNARE complex formation, mimicking botulinum toxin's mechanism but via a much weaker pathway:
Synaptosomal-Associated Protein (SNAP-25) is one of the SNARE proteins required for vesicle fusion at neuromuscular junctions. In facial muscles, SNARE-mediated acetylcholine vesicle fusion drives muscle contraction and wrinkle formation over time.
Snap-8's 8-amino-acid sequence shares a portion of the SNAP-25 N-terminal sequence. The mimic peptide competes with native SNAP-25 for SNARE complex assembly, partially blocking complete SNARE complex formation.
With incomplete SNARE complex formation, acetylcholine vesicle fusion at neuromuscular junctions is reduced - muscle contraction force decreases, repeated contractions create less wrinkle formation.
Snap-8 has moderate skin penetration but does not reach deep muscle layers. The cosmetic effect is primarily on superficial expression lines, not deep muscle activity.
Botulinum toxin enzymatically cleaves SNAP-25 (irreversible at the receptor), producing dramatic and lasting (3-6 month) muscle paralysis from a single injection. Snap-8 is a competitive mimic (reversible) requiring continuous topical application for modest effect. Magnitudes of effect differ by orders of magnitude.
Sequence contains Met - chemistry conflict with copper-conjugated peptides like GHK-Cu in formulation contexts (less relevant for topical use where formulation chemistry can manage this).
Weeks 1-4: minimal subjective change.
Weeks 4-12: subtle expression line smoothing.
Weeks 12+: visible cosmetic effect on superficial expression lines (modest).
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
The test product of HA-MNs comprises arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine, and seaweed extracts.
The test product of HA-MNs comprises arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine, and seaweed extracts.
Evidence scope. Human hyaluronic-acid microneedle patch study; not evidence for 5-10% conventional topical application.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Complete regimen: 5-10% topical formulation via Topical (primary), 1-2x daily. The verified row supports only the narrower dose/route boundary stated above, not every element of the displayed regimen.
Mechanism: Snap-8 inhibits SNARE complex formation, mimicking botulinum toxin's mechanism but via a much weaker pathway: 1. SNARE Complex Function: Synaptosomal-Associated Protein (SNAP-25) is one of the SNARE proteins required for. No checked live abstract supported this full mechanistic claim at the card's formulation/route without extrapolation.
Primary safety claim: Mild skin irritation. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
Topical; minimal systemic absorption
Topical 1-3 hours
Days to weeks for cumulative effect
Topical via skin penetration; systemic minimal
Continuous use required for sustained effect
Local proteolysis
Storage. Topical formulations: room temperature stable per manufacturer. Lyophilized peptide: refrigerate.
Cosmetic ingredient (not pharmaceutical). Approved as cosmetic ingredient in EU, US, and most jurisdictions. Not FDA-approved as therapeutic. Lubrizol/Lipotec maintains the ingredient registration.
Put it to work
Open Snap-8 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Snap-8 in the app →Go deeper
The complete Snap-8 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.